In focus · trending topic

gastrointestinal diseases

9 stories · following the connections

Ritter Pharmaceuticals Announces 1-for-10 Reverse Stock Split

By Nasdaq OMXMar 22, 2018, 3:35 PM UTC

Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

By Nasdaq OMXMar 19, 2018, 10:35 AM UTC

Ritter Pharmaceuticals, Inc.’s Board Approves 1-for-10 Reverse Stock Split

By Nasdaq OMXMar 1, 2018, 9:20 PM UTC

Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical Development, Ahead of the Launch of its Phase 3 Clinical Trial

By Nasdaq OMXJan 29, 2018, 2:01 PM UTC

Ritter Pharmaceuticals Presents at the 10th Annual LD Micro Conference on December 5, 2017

By Nasdaq OMXNov 29, 2017, 2:30 PM UTC

Ritter Pharmaceuticals Presents at the 5th Microbiome R&D Business Collaboration Forum / 2nd Annual Probiotic Congress

By Nasdaq OMXNov 2, 2017, 8:51 PM UTC

Ritter Pharmaceuticals, Inc. Prices $23,000,000 Public Offering

By Nasdaq OMXSep 29, 2017, 12:00 PM UTC

RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules

By Nasdaq OMXAug 17, 2017, 11:00 AM UTC